The cohort study published in the NEJM revealed that a 5 day course of the drug compared to amoxicillin was associated with twice the risk of death, translating to 47 extra cardiovascular deaths for every million courses of azithromycin or 245 extra deaths in subjects with baseline heart disease.    The FDA has released a statement saying that it will evaluate the study to see if changes should be made to the product label.  Will you begin recommending alternative antibiotics especially for patients with baseline heart disease?